相关实验视频
Updated: Sep 15, 2025

08:06
Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues
Published on: July 8, 2020
5.6K
鲁克索利提尼布通过减弱IL-13缓解炎症并加强皮肤屏障功能
Li Fang Koh1, Muhammad Jasrie Firdaus1, Yohei Natsuaki1
1A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Experimental dermatology
|July 18, 2025
概括
鲁克索利提尼布有效地减少了亚托皮性皮炎 (AD) 模型中的炎症和. 该药物通过降低IL-13的调节来改善皮肤屏障功能,支持其在阿兹海默症患者的临床疗效.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚托皮炎 (AD) 是一种常见的炎症性皮肤疾病,具有障碍障碍功能和免疫失调.
- 卢克索利提尼布是一种Janus激酶 (JAK) 抑制剂,是治疗AD的新兴药物疗法.
研究的目的:
- 用小鼠和人类皮肤模型评估ruxolitinib在缓解AD相关症状方面的疗效.
- 调查卢克索利提尼布对皮肤屏障完整性和炎症影响的分子机制.
主要方法:
- 用MC903/ruxolitinib治疗的小鼠来评估耳朵胀,组织学,,生物标志物和免疫细胞.
- 免疫组织化学和转录组分析在用细胞因子治疗的人类复原皮肤 (RHS) 和用 ruxolitinib 治疗的人类皮肤扩展器上进行.
主要成果:
- 卢克索利替尼治疗减少了小鼠的炎症,耳朵胀和,T细胞和IL-13的减少.
- 转录组分析显示,在细胞因子治疗的RHS中,STAT3增加和FLG减少.
- 接受鲁克索利提尼布治疗的人类皮肤扩展体显示皮肤屏障基因 (FLG,FLG2,LOR) 的表达增加,IL13RA1.1的减少.
结论:
- 鲁克索利提尼布通过降低IL-13的调节和增强皮肤屏障蛋白质,有效地减少AD模型中的炎症和.
- 这些发现与临床数据一致,该数据显示,在接受ruxolitinib治疗的AD患者中,SCORAD和的减少.
相关概念视频
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K
Renewal of Skin Epidermal Stem Cells
2.6K
The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular...
2.6K
TGF - β Signaling Pathway
7.7K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
469
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
469
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271

